ライフサイエンスコーパス: ulcerative

1 que (1172 [96%]) large (>/=15 cm, 444 [36%]) ulcerative (805 [66%]) lesion of the lower limb (733 [60

2 ients had a history of unique neonatal-onset ulcerative and cutaneous lesions in cold-sensitive regio

3 Ulcerative and indeterminate colitis patients who underw

4 Hemorrhagic cystitis is an inflammatory and ulcerative bladder condition associated with systemic ch

5 vere psoriasis (1.29; 95% CI, 1.12-1.47) and ulcerative colitis (1.26; 95% CI, 1.14-1.40).

6 asis (85 232), bullous skin diseases (4284), ulcerative colitis (12 203), Crohn's disease (7628), inf

7 y of patients had Crohn's disease (40.3%) or ulcerative colitis (30.5%).

8 relapse in patients with Crohn's disease or ulcerative colitis (approximately 75% of patients experi

9 s disease (hazard ratio 2.19; 1.44-3.34) and ulcerative colitis (hazard ratio 1.63; 1.18-2.27) was si

10 follow-up, 48 men were newly diagnosed with ulcerative colitis (incidence rate (IR) = 36/100,000 per

11 ADT was associated with a decreased risk of ulcerative colitis (IR = 24/100,000 PY vs. IR = 50/100,0

12 ens from the terminal ileum of patients with ulcerative colitis (n = 20), CD (n = 20), or individuals

13 colon tissues from age-matched patients with ulcerative colitis (n=10) vs without IBD (n=8, controls)

14 strong colonic expression, protects against ulcerative colitis (overall P=6.89 x 10(-7), odds ratio=

15 ated macular degeneration (P=1.4 x 10(-12)), ulcerative colitis (P<1.0 x 10(-20)), type 2 diabetes (P

16 ide genetic correlation (rG) between PSC and ulcerative colitis (UC) (rG = 0.29) was significantly gr

17 was associated with Crohn's disease (CD) and ulcerative colitis (UC) among Moroccan patients, and eva

18 The studies included 67,057 patients with ulcerative colitis (UC) and 75,971 patients with Crohn's

19 tic approaches fail to differentiate between ulcerative colitis (UC) and Crohn's colitis (CC) in one-

20 The inflammatory bowel diseases (IBD) ulcerative colitis (UC) and Crohn's disease (CD) cause s

21 AIMS: The inflammatory bowel diseases (IBD) ulcerative colitis (UC) and Crohn's disease (CD) cause s

22 al tract of uncertain origin, which includes ulcerative colitis (UC) and Crohn's disease (CD).

23 ined from patients with PSC with and without ulcerative colitis (UC) and explanted PSC livers.

24 to determine LP macrophage phenotypes in CD, ulcerative colitis (UC) and healthy controls (HC), and i

25 ase (PIBD), comprising Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease u

26 ulate inflammation during the development of ulcerative colitis (UC) and progression to colitis-assoc

27 owel disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC) and to compare the occurrence of

28 Ulcerative colitis (UC) belongs to inflammatory bowel di

29 the mainstay treatments in the management of ulcerative colitis (UC) but up to a third of patients wi

30 Ulcerative colitis (UC) can be treated with surgery or m

31 hnique used to measure endoscopic healing in ulcerative colitis (UC) clinical trials.

32 It is not clear why some patients with ulcerative colitis (UC) do not respond to treatment with

33 The medical management of ulcerative colitis (UC) has improved through the develop

34 hat affect risk for Crohn's disease (CD) and ulcerative colitis (UC) in a case-only study of patients

35 rrelated with development and progression of ulcerative colitis (UC) in human patients.

36 Ulcerative colitis (UC) is a chronic, inflammatory bowel

37 Ulcerative colitis (UC) is a chronic, relapsing and debi

38 Ulcerative colitis (UC) is difficult to treat, and stand

39 Diarrhea associated with ulcerative colitis (UC) occurs primarily as a result of

40 The odds of having ulcerative colitis (UC) or Crohn disease (CD) were eleva

41 ospective study with Crohn's disease (CD) or ulcerative colitis (UC) patients initiating anti-integri

42 ndrome (IBS) is more common in patients with ulcerative colitis (UC) than expected.

43 mmon long-term complication in patients with ulcerative colitis (UC) undergoing proctocolectomy with

44 r role in pediatric Crohn's disease (CD) and ulcerative colitis (UC) we obtained mucosal biopsies of

45 and TJP1) and IBD, Crohn's disease (CD), or ulcerative colitis (UC) were investigated.

46 y bowel diseases (IBD; Crohn's disease (CD), ulcerative colitis (UC)).

47 cting the colon such as medically refractory ulcerative colitis (UC), aggressive Crohn's disease (CD)

48 , colorectal cancer (CRC), benign neoplasms, ulcerative colitis (UC), and Crohn's disease (CD) betwee

49 main forms of irritable bowel disease (IBD), ulcerative colitis (UC), and Crohn's disease (CD).

50 The ST2/IL-33 pathway has been related to ulcerative colitis (UC), and soluble ST2 (sST2), to dise

51 es (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are complex chronic inflammator

52 In both Crohn's disease (CD) and ulcerative colitis (UC), the gut is massively infiltrate

53 Human ulcerative colitis (UC), UC-associated CRC, and sporadic

54 transabdominal minimal invasive approach in ulcerative colitis (UC), using the comprehensive complic

55 ype 2 immune response in the pathogenesis of ulcerative colitis (UC)-few data are available from trea

56 osal inflammatory cytokines in patients with ulcerative colitis (UC).

57 in patients with moderate to severely active ulcerative colitis (UC).

58 (CD) and for 8 SNPs in 5 genes of paediatric ulcerative colitis (UC).

59 al role of Escherichia coli in the course of ulcerative colitis (UC).

60 r been adequately evaluated in patients with ulcerative colitis (UC).

61 nosed with Crohn's disease (CD) and 361 with ulcerative colitis (UC).

62 both in healthy mice and in a mouse model of ulcerative colitis (UC).

63 owel diseases (IBDs): Crohn disease (CD) and ulcerative colitis (UC).

64 f fecal microbiota transplantation (FMT) for ulcerative colitis (UC).

65 thelial barrier defenses are associated with ulcerative colitis (UC).

66 ed in patients with Crohn's disease (CD) and ulcerative colitis (UC).

67 sponse and remission in patients with active ulcerative colitis (UC).

68 al pouch-anal anastomosis (IPAA) surgery for ulcerative colitis (UC).

69 ating patients with Crohn's disease (CD) and ulcerative colitis (UC).

70 ression and function during human and murine ulcerative colitis (UC).

71 se (IBD), including Crohn's disease (CD) and ulcerative colitis (UC).

72 ging treatment options for the management of ulcerative colitis (UC).

73 signalling pathway has been associated with ulcerative colitis (UC).

74 nastomosis (IRA) failure after colectomy for ulcerative colitis (UC).

75 ving pathways) contribute to pathogenesis of ulcerative colitis (UC).

76 0.05 for Crohn's disease (CD), p = 0.03 for Ulcerative Colitis (UC); Odds Ratio 1.09, 95 % Confidenc

77 n disease-subtypes, Crohn's disease (CD) and ulcerative colitis (UC); these subtypes share overlappin

78 nts [123 with Crohn disease (CD) and 94 with ulcerative colitis (UC)] were analyzed; 75 of 150 (50%)

79 om patients with Crohn's disease (n = 61) or ulcerative colitis (UC, n = 74) or from patients without

80 R, $87335-$126541]), and total colectomy for ulcerative colitis (WIQR, $24497; median, $34910 [IQR, $

81 disease +11.1% [95% CI 4.8-17.8] and APC for ulcerative colitis +14.9% [10.4-19.6]) and Taiwan (APC f

82 Crohn's disease +4.0% [1.0-7.1] and APC for ulcerative colitis +4.8% [1.8-8.0]).

83 2 per 100 000 in Germany) and North America (ulcerative colitis 286 per 100 000 in the USA; Crohn's d

84 t reported prevalence values were in Europe (ulcerative colitis 505 per 100 000 in Norway; Crohn's di

85 ease [n = 356] or the partial Mayo score for ulcerative colitis [n = 253]).

86 matory bowel disease (Crohn disease [CD] and ulcerative colitis [UC]) and diabetic nephropathy (macro

87 tory bowel disease (IBD; Crohn disease [CD], ulcerative colitis [UC]) and is inversely related to typ

88 h IBD (43 with Crohn's disease [CD], 23 with ulcerative colitis [UC]), and 30 children without IBD (c

89 535 consecutive patients with IBD (211 with ulcerative colitis [UC], 234 with Crohn's disease [CD];

90 roscopy in 110 consecutive subjects (31 with ulcerative colitis [UC], 57 with Crohn's disease [CD], a

91 Guided by the Pediatric Ulcerative Colitis Activity Index (PUCAI), patients rece

92 ween colitis-associated cancer and different ulcerative colitis activity states.

93 onoscopy; 322 were screened by MRC (222 with ulcerative colitis and 100 with Crohn's disease).

94 were present there in 11 of 13 patients with ulcerative colitis and 14 of 15 with Crohn's disease.

95 nflammatory bowel diseases (n = 119; 59 with ulcerative colitis and 60 with Crohn's disease).

96 livered by acute CS had an increased risk of ulcerative colitis and celiac disease, whereas children

97 sregulated in a range of diseases, including ulcerative colitis and colorectal cancer.

98 nflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn disease, are chronic inflam

99 5, LRRK2, and MAPT for rheumatoid arthritis, ulcerative colitis and Crohn disease.

100 Ulcerative colitis and Crohn's disease are the two main

101 Ulcerative colitis and Crohn's disease are the two predo

102 Conventional end points for trials in ulcerative colitis and Crohn's disease have been based o

103 To be included in the systematic review, ulcerative colitis and Crohn's disease needed to be repo

104 lammatory bowel diseases (IBD, which include ulcerative colitis and Crohn's disease) are abdominal pa

105 hitecture of the inflammatory bowel diseases ulcerative colitis and Crohn's disease, we sequenced the

106 Inflammatory bowel disease includes ulcerative colitis and Crohn's disease.

107 had been admitted, unscheduled, with severe ulcerative colitis and failed to respond to intravenous

108 bitor of MMP9, has shown promise in treating ulcerative colitis and gastric cancer.

109 ch as Crohn disease, multiple sclerosis, and ulcerative colitis and hereby elucidate the molecular me

110 strongest associations were observed between ulcerative colitis and HLA rs9271366 (P = 7.5 x 10(-6)),

111 in human ileal tissues from individuals with ulcerative colitis and intestinal carcinomas, also have

112 In both humans with long-standing ulcerative colitis and mouse models of colitis-associate

113 Ps in IL23R, IL12B, and C2orf43; and between ulcerative colitis and SNPs near HDAC11 and near LINC009

114 reased compared with patients with quiescent ulcerative colitis and that colitis was attenuated in IL

115 They were all diagnosed as ulcerative colitis and treated with mesalazine orally.

116 at will be available include vedolizumab for ulcerative colitis and ustekinumab for Crohn's disease,

117 Crohn's disease, ileal Crohn's disease, and ulcerative colitis are all genetically distinct from eac

118 Crohn's disease and ulcerative colitis are heterogeneous inflammatory bowel

119 Celiac disease, Crohn disease and ulcerative colitis are inflammatory disorders of the gas

120 Crohn's disease and ulcerative colitis are the primary inflammatory bowel di

121 Crohn's disease and ulcerative colitis are the two major forms of inflammato

122 erative colitis) than by Crohn's disease and ulcerative colitis as currently defined.

123 tients undergoing colonoscopic screening for ulcerative colitis at the Leicester General Hospital, Le

124 tiating profiles between Crohn's disease and ulcerative colitis by means of (orthogonal) partial leas

125 T cells serves an important role in driving ulcerative colitis by regulating intestinal epithelial c

126 In contrast, ulcerative colitis causes an interstitial lymphocytic an

127 ively, who had moderately to severely active ulcerative colitis despite previous conventional therapy

128 Mayo Clinic endoscopic subscores (MCSe) and ulcerative colitis endoscopic index of severity (UCEIS)

129 ontaneous production of cytokines from human ulcerative colitis explants.

130 Intestinal tissues from patients with ulcerative colitis expressed significantly lower levels

131 ries, with a history (>/=3 months) of active ulcerative colitis extending more than 15 cm beyond the

132 een achieved and the patient is remission of ulcerative colitis for the last six months.

133 ncidence or prevalence of Crohn's disease or ulcerative colitis from 1990 or later.

134 sk estimates of colorectal cancer related to ulcerative colitis from Asia vary.

135 se for terms related to colorectal cancer in ulcerative colitis from inception to July 1, 2016.

136 Conversely, patients with ulcerative colitis had an increased risk of liver diseas

137 from patients with CD and from patients with ulcerative colitis had distinct changes in DNA methylati

138 Previous retrospective studies of paediatric ulcerative colitis have had limited ability to describe

139 d risk of surgery, while former smokers with ulcerative colitis have increased risk of colectomy.

140 Patients with ulcerative colitis have mucosal inflammation starting in

141 surgery in patients with Crohn's disease and ulcerative colitis have reached inconsistent conclusions

142 diseases (IBD) known as Crohn's disease and ulcerative colitis have shown strong evidence of associa

143 potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.

144 against the development of Crohn disease and ulcerative colitis in humans.

145 ion of mucosal integrity, and contributes to ulcerative colitis in mice and humans.

146 Treatments for ulcerative colitis include 5-aminosalicylic acid drugs,

147 Ulcerative colitis is a chronic inflammatory disease aff

148 Ulcerative colitis is an established risk factor for col

149 The therapeutic armamentarium for ulcerative colitis is expanding, and the number of drugs

150 The patient of ulcerative colitis is increasing every year and it is an

151 nditions in patients with Crohn's disease or ulcerative colitis is necessary for their total care and

152 m is not understood, and the role of Nod2 in ulcerative colitis is not known.

153 The increased risk of colorectal cancer in ulcerative colitis is well known.

154 dian age 14.1 years; Crohn's disease n = 22, ulcerative colitis n = 26, unclassified colitis n = 11)

155 solated from fecal samples of a patient with ulcerative colitis on the basis of their ability to caus

156 onic tissues from human subjects with active ulcerative colitis or Crohn's disease, implicating the l

157 ith CD, whereas 12 patients had a history of ulcerative colitis or were strongly suspected of CD base

158 nt (rs36095412, p.R179X, genotyped in 11,148 ulcerative colitis patients and 295,446 controls, MAF=up

159 B1, 2/6 Crohn's disease patients are B2, 2/2 ulcerative colitis patients are S2.

160 Macrophages from controls and ulcerative colitis patients carrying the IBD-risk rs1075

161 Fecal supernatants from ulcerative colitis patients induced permeability in the

162 ct from gut microbiota collected from either ulcerative colitis patients or healthy controls, with di

163 nd PAR2(-/-) mice by fecal supernatants from ulcerative colitis patients was assessed.

164 ll-characterized large-duct PSC patients, 96 ulcerative colitis patients, and 100 healthy controls.

165 ression was increased in tissue samples from ulcerative colitis patients.

166 e curve (AUC) of scores from the Crohn's and Ulcerative Colitis Questionnaire (CUCQ) completed by par

167 outcomes of patients with moderate to severe ulcerative colitis receiving tofacitinib, although at an

168 outcomes of patients with moderate to severe ulcerative colitis receiving tofacitinib.

169 tic architecture of Crohn's disease (CD) and ulcerative colitis remain incompletely defined.

170 hn's disease and 15 (83.3%) of 18 studies on ulcerative colitis reported stable or decreasing inciden

171 ls, models of neurodegenerative diseases and ulcerative colitis suggest the likelihood of this scenar

172 The only study in patients with ulcerative colitis supported continued immunomodulator u

173 lightly higher rate of clinical remission of ulcerative colitis than placebo.

174 soriasis, primary sclerosing cholangitis and ulcerative colitis to investigate pleiotropy and the rel

175 he response of children newly diagnosed with ulcerative colitis to standardised initial therapy and i

176 We analyzed data collected during the Active Ulcerative Colitis Trials (ACT-1 and ACT-2) to assess re

177 Ulcerative colitis usually presents with bloody diarrhoe

178 found no difference between individuals with ulcerative colitis vs Crohn's disease.

179 A 37-year-old man with ulcerative colitis was admitted to the hospital because

180 of IL19 in biopsies of patients with active ulcerative colitis was increased compared with patients

181 of colorectal cancer in Asian patients with ulcerative colitis was similar to recent estimates in Eu

182 Former smokers with ulcerative colitis were at increased risk of colectomy (

183 e genes were also activated in patients with ulcerative colitis where chronic inflammation predispose

184 "future" cancer progression in patients with ulcerative colitis who did and did not develop colon can

185 patients with moderately-to-severely active ulcerative colitis who had not responded to conventional

186 patients with moderately-to-severely active ulcerative colitis who participated in ACT-1 or ACT-2; e

187 Crohn's disease and 33 patients with active ulcerative colitis who were candidates to receive inflix

188 miRNA signature identified in mice predicted ulcerative colitis with 83.3% accuracy.

189 sis included a total of 31 287 patients with ulcerative colitis with a total of 293 reported colorect

190 In the treatment of ulcerative colitis with mesalazine, we should pay attent

191 id arthritis, multiple sclerosis, lupus, and ulcerative colitis) and in some forms of cancer.

192 bowel disease (IBD; i.e. Crohn's disease or ulcerative colitis) and typically developing children wi

193 ts (19,713 with Crohn's disease, 14,683 with ulcerative colitis) genotyped on the Immunochip array.

194 Thirty patients (15 Crohns disease, 15 ulcerative colitis) participated, and 92 segmental pairs

195 rohn's disease, colonic Crohn's disease, and ulcerative colitis) than by Crohn's disease and ulcerati

196 variate, Crohn's disease and no IBD (both vs ulcerative colitis) were associated with a lower risk of

197 liac disease, multiple sclerosis, lupus, and ulcerative colitis), the GWAS association arises from mu

198 ts (16,902 with Crohn's disease, 12,597 with ulcerative colitis).

199 (P = .18 for Crohn's disease and P = .14 for ulcerative colitis).

200 ents with IBD and colorectal cancer (15 with ulcerative colitis, 14 with Crohn's disease, and 2 with

201 1088 patients with Crohn's disease, 361 with ulcerative colitis, 62 with IBD type unknown, and 1797 c

202 ected in intestinal samples of patients with ulcerative colitis, a condition associated with increase

203 nd their metabolism is often dysregulated in ulcerative colitis, a major category of inflammatory bow

204 als with Crohn disease, 149 individuals with ulcerative colitis, and 142 healthy control subjects to

205 Crohn's disease, 19/100,000 person-years for ulcerative colitis, and 5/100,000 person-years for IBD u

206 probiotic activity used in the treatment of ulcerative colitis, and a carcinogenic activity under ho

207 increased susceptibility to Crohn's disease, ulcerative colitis, and asthma.

208 nts with Crohn's disease and 8 patients with ulcerative colitis, and from normal colon of 8 healthy i

209 and compared with other Crohn's phenotypes, ulcerative colitis, and non-Crohn's patients.

210 f recovery from bone marrow transplantation, ulcerative colitis, and partial hepatectomy.

211 ue therapeutic approach for the treatment of ulcerative colitis, and phase 3 studies have been planne

212 lved in the pathogenesis of Crohn's disease, ulcerative colitis, and pouchitis.

213 arthritis and significantly least similar to ulcerative colitis, and provided support for three addit

214 el diseases (IBD), such as Crohn disease and ulcerative colitis, are chronic relapsing conditions tha

215 tor cells, including pathogenic TH2 cells in ulcerative colitis, but is expressed poorly or not at al

216 of similar efficacy in treating acute severe ulcerative colitis, but there has been no comparative ev

217 ative regulator of innate immunity) in human ulcerative colitis, by comparing monozygotic twins and o

218 atures for different IBD subtypes, including ulcerative colitis, colonic Crohn's disease and ileal Cr

219 uced colitis and human colonic biopsies from ulcerative colitis, compared with controls.

220 g obesity, atherosclerosis, Crohn's disease, ulcerative colitis, drug toxicity, and even autism.

221 on carcinogenesis and in human patients with ulcerative colitis, even in tissue that appears histolog

222 of CCDC88b in patients with Crohn disease or ulcerative colitis, identifying that expression correlat

223 l disease (IBD), including Crohn disease and ulcerative colitis, is characterized by chronic intestin

224 anti-tumor necrosis factor (TNF) therapy in ulcerative colitis, its effects on postoperative outcome

225 ents were allocated to three disease groups (ulcerative colitis, n=37; dysplasia, n=2; colitis-associ

226 rhea (ICD) in rhesus macaques also resembles ulcerative colitis, one form of human inflammatory bowel

227 or histological features of Crohn's disease, ulcerative colitis, or IBD unclassified.

228 ears old or younger and had Crohn's disease, ulcerative colitis, or IBD-unclassified with 24,543.0 pa

229 Defined as a diagnosis of Crohn's disease, ulcerative colitis, or inflammatory bowel disease unclas

230 tissues from healthy subjects, patients with ulcerative colitis, patients with celiac disease, and pa

231 mmatory diseases such as Crohn disease (CD), ulcerative colitis, psoriasis, and type 1 diabetes.

232 tween PD and type 1 diabetes, Crohn disease, ulcerative colitis, rheumatoid arthritis, celiac disease

233 heimer's Project stage 1) and Crohn disease, ulcerative colitis, rheumatoid arthritis, type 1 diabete

234 Finally, in patients with ulcerative colitis, SGPP2 expression was elevated in col

235 iants and heterozygous advantage observed in ulcerative colitis, suggesting an important role of the

236 estigated to delineate mechanisms regulating ulcerative colitis, the role of acid ceramidase (AC) in

237 In patients with ulcerative colitis, there was no difference in the need

238 the risk of relapse, to discriminate CD from ulcerative colitis, to select candidates to anti-tumor n

239 patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as in

240 This case report presents a patient with ulcerative colitis, with thrombotic complication of the

241 ne patients out of 100 (Crohn's disease- 67, ulcerative colitis- 23 and IBDU-10) had known TPMT mutat

242 animod in 197 adults with moderate-to-severe ulcerative colitis.

243 e, mostly shared between Crohn's disease and ulcerative colitis.

244 evelopment of colon cancer as found in human ulcerative colitis.

245 se variant in ADCY7 that doubles the risk of ulcerative colitis.

246 section in patients with Crohn's disease and ulcerative colitis.

247 lammatory bowel disease, Crohn's disease and ulcerative colitis.

248 ged 4-17 years who were newly diagnosed with ulcerative colitis.

249 ancer cohort (p=0.0061) compared with active ulcerative colitis.

250 hallmark of the inflammatory bowel disease, ulcerative colitis.

251 th chronic obstructive pulmonary disease and ulcerative colitis.

252 dysfunction that underlies the pathology of ulcerative colitis.

253 r HLA-DRB1*01:03 in both Crohn's disease and ulcerative colitis.

254 and progression of disease in patients with ulcerative colitis.

255 , range 22-67), 6/8 Crohn's disease, and 2/8 ulcerative colitis.

256 h affects the orbit far more frequently than ulcerative colitis.

257 ransplantation and response to Infliximab in ulcerative colitis.

258 gene and linked them with increased risk for ulcerative colitis.

259 arge bowel inflammation that resembles human ulcerative colitis.

260 to identify patients 18 years or older with ulcerative colitis.

261 decreased in patients with colon cancer and ulcerative colitis.

262 d outcomes of adults with moderate-to-severe ulcerative colitis.

263 patients with moderately-to-severely active ulcerative colitis.

264 .1 and interleukin 9 (IL-9) in patients with ulcerative colitis.

265 human patients with Clostridium difficile or ulcerative colitis.

266 in gut mucosa among associations stronger in ulcerative colitis.

267 emission in patients with moderate to severe ulcerative colitis.

268 evalence (69 studies) of Crohn's disease and ulcerative colitis.

269 trials of tofacitinib therapy in adults with ulcerative colitis.

270 mine serves as the gold standard in treating ulcerative colitis.

271 on the risk of colorectal cancer related to ulcerative colitis.

272 ies for psoriasis, rheumatoid arthritis, and ulcerative colitis.

273 3% and 0.7% (odds ratio 1.75; 1.44-2.13) for ulcerative colitis.

274 ransplantation and response to Infliximab in ulcerative colitis.

275 l Modification (ICD-9-CM) diagnosis code for ulcerative colitis.

276 00547659 in patients with moderate to severe ulcerative colitis.

277 icular disease, benign colonic neoplasm, and ulcerative colitis/regional enteritis were included.

278 efficacy in patients with moderate-to-severe ulcerative colitis; however, complex factors determine t

279 Australia (23 with Crohn's colitis, 29 with ulcerative colitis; median age, 45.0 y; 60% male; mean I

280 Ketamine-induced ulcerative cystitis (KIC) initially damaged the bladder

281 The etiology of this ulcerative dermatosis has not been identified, although

282 Of 53 patients 51 (96%) had ulcerative disease.

283 Ulcerative jejunitis in association with celiac disease

284 t is to describe the first pediatric case of ulcerative jejunitis in celiac disease, diagnosed by cap

285 ion of a gluten free diet, also suggest that ulcerative jejunitis is not always associated with refra

286 onfirmed the diagnosis of celiac disease and ulcerative jejunitis.

287 agnosis of celiac disease and its associated ulcerative jejunitis.

288 tions including a rare complication known as ulcerative jejunitis.

289 bited a significantly larger and more severe ulcerative lesion than mice infected with the wild type.

290 These ulcerative lesions resolved within a month after discont

291 cute and relapsing symptoms characterized by ulcerative lesions.

292 n, presented a spontaneous healing after the ulcerative phase despite stable bacterial load, and myco

293 remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis.

294 ission in 546 patients with mild to moderate ulcerative proctitis or ulcerative proctosigmoiditis who

295 colon, to induce remission in patients with ulcerative proctitis or ulcerative proctosigmoiditis.

296 ith mild to moderate ulcerative proctitis or ulcerative proctosigmoiditis who received budesonide foa

297 ion in patients with ulcerative proctitis or ulcerative proctosigmoiditis.

298 th mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis.

299 by vasculopathy, interstitial lung disease, ulcerative skin lesions, and premature death.

300 ive, A. invadans, which causes the epizootic ulcerative syndrome on fish.